SCHEMBL22982979

SCHEMBL22982979

COc1ccc(-n2cc(C)nn2)c(CNC(=O)c2cn(Cc3ccc4c(c3)CN(C)CC4)nn2)c1F

nearest known ligand 0.81

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 P03952 12/20 0.81
▸ F11 P03951 10/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29407387 1.00 KLKB1 (0.81) KLKB1F11
SCHEMBL29407600 0.90 KLKB1 (1.00) KLKB1F11
SCHEMBL29407465 0.89 KLKB1 (0.77) KLKB1F11
SCHEMBL22981502 0.87 F11 (0.85) KLKB1F11
SCHEMBL29407281 0.87 F11 (0.85) KLKB1F11
SCHEMBL29405871 0.87 F11 (0.83) KLKB1F11
SCHEMBL29407031 0.87 KLKB1 (0.85) KLKB1F11
SCHEMBL22982053 0.87 KLKB1 (0.85) KLKB1F11
SCHEMBL29407537 0.87 KLKB1 (1.00) KLKB1F11
SCHEMBL22993391 0.85 KLKB1 (1.00) KLKB1F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4010333-A1 PLASMA KALLIKREIN INHIBITORS Kalvista Pharmaceuticals Limited (GB) 2022-06-15 — — EP claimed
WO-2021028645-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO claimed
WO-2021028649-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO claimed
EP-4010333-A1 PLASMA KALLIKREIN INHIBITORS Kalvista Pharmaceuticals Limited (GB) 2022-06-15 — — EP disclosed
WO-2021028649-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO disclosed
WO-2021028645-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO disclosed
Send feedback